Antidiuretic effects of the endothelin receptor antagonist avosentan

Frontiers in Physiology

Volumn 3 APR, Issue , 2012, Pages

  Baltatu, Ovidiu Constantin ^a,b   Iliescu, Radu ^b   Zaugg, Christian E ^c   Reckelhoff, Jane F ^d   Louie, Pat ^e   Schumacher, Christoph ^e   Campos, Luciana Aparecida ^a,b  

^a UNIVERSIDADE CAMILO CASTELO BRANCO   (Brazil)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Diuresis; Endothelin receptor antagonist; Fluid retention; Renal

Indexed keywords

EID: 84866270574     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00103     Document Type: Article

References (35)

1. Anand, I., McMurray, J., Cohn, J. N., Konstam, M. A., Notter, T., Quitzau, K., Ruschitzka, F., and Luscher, T. F. (2004). Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364, 347-354.
2. Bogzil, A. H., and Ashton, N. (2009). Relaxin-induced changes in renal function and RXFP1 recep-tor expression in the female rat. Ann. N. Y. Acad. Sci. 1160, 313-316.
3. Bogzil, A. H., Eardley, R., and Ashton, N. (2005). Relaxin-induced changes in renal sodium excretion in the anesthetized male rat. Am.J.Physiol. Regul. Integr. Comp. Physiol. 288, R322-R328.
4. Bruno, C. M., Meli, S., Marcinno, M., Ierna, D., Sciacca, C., and Neri, S. (2002). Plasma endothelin-1 levels and albumin excretion rate in nor-motensive, microalbuminuric type 2 diabetic patients. J. Biol. Regul. Homeost. Agents 16, 114-117.
5. Campos, L. A., Couto, A. S., Iliescu, R., Santos, J. A., Santos, R. A., Ganten, D., Campagnole-Santos, M. J., Bader, M., and Baltatu, O. (2004). Differential regulation of central vasopressin receptors in transgenic rats with low brain angiotensinogen. Regul. Pept. 119, 177-182.
6. Danielson, L. A., Sherwood, O. D., and Conrad, K. P. (1999). Relaxin is a potent renal vasodilator in conscious rats. J. Clin. Invest. 103, 525-533.
7. Davenport, A. P., and Maguire, J. J. (2011). Pharmacology of renal endothelin receptors. Contrib. Nephrol. 172, 1-17.
8. De Mattia, G., Cassone-Faldetta, M., Bellini, C., Bravi, M. C., Laurenti, O., Baldoncini, R., Santucci, A., and Ferri, C. (1998). Role of plasma and urinary endothelin-1 in early dia-betic and hypertensive nephropathy. Am. J. Hypertens. 11, 983-988.
9. Dhaun, N., MacIntyre, I. M., Kerr, D., Melville, V., Johnston, N. R., Haughie, S., Goddard, J., and Webb, D. J. (2011). Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57, 772-779.
10. Dschietzig, T., Bartsch, C., Richter, C., Laule, M., Baumann, G., and Stangl, K. (2003). Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ. Res. 92, 32-40.
11. Edwards, R. M., Stack, E. J., Pullen, M., and Nambi, P. (1993). Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor. J. Pharmacol. Exp. Ther. 267, 1028-1033.
12. Gagliardini, E., Buelli, S., and Benigni, A. (2011). Endothelin in chronic proteinuric kidney disease. Contrib. Nephrol. 172, 171-184.
13. Ge, Y., Bagnall, A., Stricklett, P. K., Strait, K., Webb, D. J., Kotelevtsev, Y., and Kohan, D. E. (2006). Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal Physiol. 291, F1274- F1280.
14. Ge, Y., Stricklett, P. K., Hughes, A. K., Yanagisawa, M., and Kohan, D. E. (2005). Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am. J. Physiol. Renal Physiol. 289, F692-F698.
15. Guo, X., and Yang, T. (2006). Endothelin B receptor antagonism in the rat renal medulla reduces urine flow rate and sodium excretion. Exp. Biol. Med. (Maywood) 231, 1001-1005.
16. Haynes, W. G., and Webb, D. J. (1998). Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. 16, 1081-1098.
17. Jandeleit-Dahm, K. A., and Watson, A. M. (2012). The endothelin system and endothelin receptor antagonists. Curr. Opin. Nephrol. Hypertens. 21, 66-71.
18. Kohan, D. E., Rossi, N. F., Inscho, E. W., and Pollock, D. M. (2011). Regulation of blood pressure and salt homeostasis by endothelin. Physiol. Rev. 91, 1-77.
19. Maillard, M. P., Wang, Q., Baltatu, O. C., and Burnier, M. (2008). Do endothelin receptor antagonists induce edema through an extravasation of fluids? Evidence from an experiment in bi-nephrectomized rats. J. Hypertens. 26, S371.
20. Mann,J. F.,Green,D.,Jamerson,K.,Ruilope, L. M., Kuranoff, S. J., Littke, T., and Viberti, G. (2010). Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527-535.
21. McMurray, J. J., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G., Jondeau, G., Krum, H., Metra, M., O'Connor, C. M., Parker, J. D., Torre-Amione, G., van Veldhuisen, D. J., Lewsey, J., Frey, A., Rainisio, M., and Kobrin, I. (2007). Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298, 2009-2019.
22. Nadler, S. P., Zimpelmann, J. A., and Hebert, R. L. (1992). Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct. J. Clin. Invest. 90, 1458-1466.
23. Nakano, D., Pollock, J. S., and Pollock, D. M. (2008). Renal medullary ETB receptors produce diuresis and natriuresis via NOS1. Am. J. Physiol. Renal Physiol. 294, F1205-F1211.
24. Ohkita, M., Wang, Y., Nguyen, N. D., Tsai,Y. H., Williams, S. C., Wiseman, R. C., Killen, P. D., Li, S., Yanagisawa, M., and Gariepy, C. E. (2005). Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats. Hypertension 45, 940-946.
25. Okada, M., and Nishikibe, M. (2002). BQ-788, a selective endothelin ET(B) receptor antagonist. Cardiovasc. Drug Rev.20, 53-66.
26. Packer, M., McMurray, J., Massie, B. M., Caspi, A., Charlon, V., Cohen-Solal, A., Kiowski, W., Kostuk, W., Krum, H., Levine, B., Rizzon, P., Soler, J., Swedberg, K., Anderson, S., and Demets, D. L. (2005). Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11, 12-20.
27. Reckelhoff,J. F.,Yokota,S. D.,and Baylis, C. (1992). Renal autoregulation in midterm and late-pregnant rats. Am. J. Obstet. Gynecol. 166, 1546-1550.
28. Saleh, M. A., Pollock, J. S., and Pollock, D. M. (2011). Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 338, 263-270.
29. Schneider, M. P., Boesen, E. I., and Pollock, D. M. (2007). Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 47, 731-759.
30. Smolander, J., Vogt, B., Maillard, M., Zweiacker, C., Littke, T., Hengelage, T., and Burnier, M. (2009). Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin. Pharmacol. Ther. 85, 628-634.
31. Teerlink, J. R., Metra, M., Felker, G. M., Ponikowski, P., Voors, A. A., Weatherley, B. D., Marmor, A., Katz, A., Grzybowski, J., Unemori, E., Teichman, S. L., and Cotter, G. (2009). Relaxin for the treatment of patients with acute heart fail-ure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429-1439.
32. Teichman, S. L., Unemori, E., Teerlink, J. R., Cotter, G., and Metra, M. (2010). Relaxin: review of biology and potential role in treating heart failure. Curr. Heart Fail. Rep. 7, 75-82.
33. van Gool,A. J.,Henry,B.,and Sprengers, E. D. (2010). From biomarker strategies to biomarker activities and back. Drug Discov. Today 15, 121-126.
34. Wenzel, R. R., Littke, T., Kuranoff, S., Jurgens, C., Bruck, H., Ritz, E., Philipp, T., and Mitchell, A. (2009). Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655-664.
35. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415.